NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative
Velocity Map

Explore the Parkinson’s research intelligence diagram before entering the Neurocompute platform.

RESEARCH PAPER

CVN-424: An Advanced GPR6 Inverse Agonist in Phase III Clinical Trials for Parkinson's Disease.

PMID

41952522

Journal

Journal of medicinal chemistry

Publication Date

2026-04-09

Grade

AI Summary

This paper reports CVN-424, a GPR6 inverse agonist that has progressed to Phase III clinical trials for Parkinson's disease.

Why It Matters

A Phase III-ready, non-dopaminergic small molecule targeting a novel GPCR (GPR6) has strong translational relevance and potential to provide new symptomatic or disease-modifying strategies, though the lack of an abstract limits assessment of mechanistic and biomarker data.

Abstract

Score Breakdown

AI Score

65.0

Base Score

33.0

Rank Score

32.5

Narrative Velocity

AI Confidence

NEUROCOMPUTE VISUAL SYSTEM